SCHEMBL95547

SCHEMBL95547

CCCCCCOC(=O)CO

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.72
RAD52 P43351 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
DGKA P23743 1/20 0.59
FAAH O00519 2/20 0.58
HTR2C P28335 1/20 0.56
EPHX1 P07099 1/20 0.55
TSHR P16473 3/20 0.53
HCAR2 Q8TDS4 1/20 0.50
PRSS1 P07477 1/20 0.50
PRSS2 P07478 1/20 0.50
PRSS3 P35030 1/20 0.50
DNM1 Q05193 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
ACHE P22303 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27912518 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL27912427 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5448501 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL27895287 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL4332027 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5696640 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL1548190 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL20067027 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5440890 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH
SCHEMBL5438833 1.00 NAAA (0.72) NAAARAD52NPSR1DGKAFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1059563-B1 Agent for reducing substrate dependence of resist WAKO PURE CHEM IND LTD (JP) 2006-08-09 EP claimed
US-6586152-B1 Useful as an ingredient of a resist composition used for preparation of semiconductor devices and the like, which comprises a compound shown by the following general formula useful as an ingredient of a resist composition used for WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2003-07-01 US claimed
EP-1059563-A1 Agent for reducing substrate dependence of resist Wako Pure Chemical Industries, Ltd. (JP) 2000-12-13 EP claimed
US-12624309-B2 Enol ether properfume FIRMENICH SA (CH) 2026-05-12 US disclosed
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 US disclosed
US-20240351957-A1 ADMIXTURE TO CONTROL THE HEAT FLOW FROM MINERAL BINDER COMPOSITIONS, MINERAL BINDER COMPOSITIONS, AND PRODUCTION METHOD THEREOF SIKA TECHNOLOGY AG (CH) 2024-10-24 US disclosed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
WO-2024175602-A1 LIGHTWEIGHT CEMENTITIOUS COMPOSITION HAVING KINETIC REGULATOR SIKA TECHNOLOGY AG (CH) 2024-08-29 WO disclosed
WO-2024175610-A1 METHODS FOR THE APPLICATION IN THICK LAYER OF CEMENTITIOUS COMPOSITIONS COMPRISING KINETIC REGULATOR SIKA TECHNOLOGY AG (CH) 2024-08-29 WO disclosed
EP-4417587-A1 METHODS FOR THE APPLICATION IN THICK LAYER OF CEMENTITIOUS COMPOSITIONS COMPRISING KINETIC REGULATOR Sika Technology AG (CH) 2024-08-21 EP disclosed
EP-4417588-A1 LIGHTWEIGHT CEMENTITIOUS COMPOSITION HAVING KINETIC REGULATOR Sika Technology AG (CH) 2024-08-21 EP disclosed
WO-1994004525-A1 BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-03-03 WO disclosed
US-5286865-A Contain reactive functional group which can be chemically attached to selected polymer substrates CIBA-GEIGY CORPORATION (US) 1994-02-15 US disclosed
WO-1994001113-A1 OXYTOCIN ANTAGONIST OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1994-01-20 WO disclosed
US-5244898-A Vasopressin antagonist OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-09-14 US disclosed
US-5225402-A Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-07-06 US disclosed
EP-0514667-A1 Benzazepin derivatives as vasopressin antagonists OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-25 EP disclosed
EP-0513387-A1 ACTIVE OXYGEN INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1992-11-19 EP disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed
US-4005189-A Process of suppressing odors employing deodorants containing esters of aliphatic hydroxycarboxylic acids HENKEL & CIE G.M.B.H. (DT) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 NAAA 757/4885RAD52 1397/4885NPSR1 4881/4885
US-12624309-B2 Enol ether properfume CYP2E1, CBR1, ADH5 NAAA 2097/4885RAD52 3787/4885NPSR1 3997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.